Lilly raises 2026 non-GAAP performance margin outlook midpoint by 2.5 percentage points

• Eli Lilly raised its 2026 revenue expectations, citing strong underlying business performance.
• The performance-margin guidance midpoint increased 2.5 percentage points to reflect the revised revenue outlook.
• Acquired research and development charges pushed tax-rate expectations higher; third-quarter charges totaled $4.2 billion before tax.
• Incretin revenue grew 54% in the third quarter, driven by market growth and increased global share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.